Capecitabine 500 MG Oral Tablet — RxCUI 200328
RxNorm drug concept · Semantic clinical drug
RxCUI 200328
Semantic clinical drug · SCD
● Current RxNorm concept 35 FDA products
48 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI200328
Official nameCapecitabine 500 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped35
Package NDCs mapped48
Reported Medicaid activity (SDUD)29,934 prescriptions · 48 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Capecitabine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Capecitabine is used for several types of cancer — most commonly colorectal (colon and rectal) cancer, advanced or metastatic breast cancer, and, depending on the product, cancers...
- What kinds of cancer does capecitabine treat?
- Yes — this one really matters. You should take capecitabine within 30 minutes after eating a meal, and swallow the tablets whole with water. Taking it on an empty stomach significa...
- The most common side effects are hand-and-foot syndrome (redness, soreness, or peeling on your palms and soles), diarrhea, nausea, fatigue, and mouth sores. Many of these can be ma...
🕸️ Concept Web — How Capecitabine 500 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Capecitabine 500 MG Oral Tablet
RxCUI 200328 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Capecitabine
194000IN
-
Capecitabine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Xeloda
220961BN
-
Xeloda
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Capecitabine Oral Tablet
371250SCDF -
Capecitabine Oral Product
1158877SCDG -
Capecitabine Pill
1158878SCDG -
Capecitabine Oral Tablet [Xeloda]
368280SBDF -
Xeloda Oral Product
1186410SBDG -
Xeloda Pill
1186411SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Capecitabine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Capecitabine 500 MG
315558SCDC -
Capecitabine 500 MG Oral Tablet [Xeloda]
213293SBD -
Capecitabine 500 MG [Xeloda]
573203SBDC
-
Capecitabine 500 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Capecitabine 500 MG
SCDC · 315558 -
Capecitabine Oral Tablet
SCDF · 371250 -
Capecitabine Oral Product
SCDG · 1158877 -
Capecitabine Pill
SCDG · 1158878
Brand-Name Concepts
-
Capecitabine 500 MG Oral Tablet [Xeloda]
SBD · 213293 -
Capecitabine 500 MG [Xeloda]
SBDC · 573203 -
Capecitabine Oral Tablet [Xeloda]
SBDF · 368280 -
Xeloda Oral Product
SBDG · 1186410 -
Xeloda Pill
SBDG · 1186411 -
Xeloda
BN · 220961
📦 FDA Products & Package NDCs
35 products · 48 package NDCs
48 package NDCs map to RxCUI 200328 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00093-7473-06 | 60 TABLET, FILM COATED in 1 BOTTLE (0093-7473-06) | Capecitabine | Teva Pharmaceuticals USA, Inc. | 2014-03-07 |
| 00093-7474-89 | 120 TABLET, FILM COATED in 1 BOTTLE (0093-7474-89) | Capecitabine | Teva Pharmaceuticals USA, Inc. | 2014-03-07 |
| 16729-0072-12 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16729-072-12) | CAPECITABINE | Accord Healthcare Inc. | 2015-06-09 |
| 16729-0073-29 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16729-073-29) | CAPECITABINE | Accord Healthcare Inc. | 2015-05-20 |
| 31722-0774-60 | 60 TABLET, FILM COATED in 1 BOTTLE (31722-774-60) | capecitabine | Camber Pharmaceuticals, Inc. | 2024-03-05 |
| 31722-0775-12 | 120 TABLET, FILM COATED in 1 BOTTLE (31722-775-12) | capecitabine | Camber Pharmaceuticals, Inc. | 2024-03-05 |
| 31722-0775-60 | 60 TABLET, FILM COATED in 1 BOTTLE (31722-775-60) | capecitabine | Camber Pharmaceuticals, Inc. | 2024-04-19 |
| 51407-0639-60 | 60 TABLET, FILM COATED in 1 BOTTLE (51407-639-60) | Capecitabine | Golden State Medical Supply, Inc. | 2022-06-28 |
| 51407-0640-12 | 120 TABLET, FILM COATED in 1 BOTTLE (51407-640-12) | Capecitabine | Golden State Medical Supply, Inc. | 2022-06-28 |
| 55111-0496-05 | 500 TABLET in 1 BOTTLE (55111-496-05) | capecitabine | Dr. Reddy's Laboratories Limited | 2020-12-10 |
| 55111-0496-60 | 60 TABLET in 1 BOTTLE (55111-496-60) | capecitabine | Dr. Reddy's Laboratories Limited | 2020-12-10 |
| 55111-0497-04 | 120 TABLET in 1 BOTTLE (55111-497-04) | capecitabine | Dr. Reddy's Laboratories Limited | 2020-12-10 |
| 55111-0497-05 | 500 TABLET in 1 BOTTLE (55111-497-05) | capecitabine | Dr. Reddy's Laboratories Limited | 2020-12-10 |
| 59651-0204-10 | 1 BLISTER PACK in 1 CARTON (59651-204-10) / 10 TABLET in 1... | Capecitabine | Aurobindo Pharma Limited | 2018-04-17 |
| 59651-0204-60 | 60 TABLET in 1 BOTTLE (59651-204-60) | Capecitabine | Aurobindo Pharma Limited | 2018-04-17 |
| 59651-0205-08 | 120 TABLET in 1 BOTTLE (59651-205-08) | Capecitabine | Aurobindo Pharma Limited | 2018-04-17 |
| 59651-0205-10 | 1 BLISTER PACK in 1 CARTON (59651-205-10) / 10 TABLET in 1... | Capecitabine | Aurobindo Pharma Limited | 2018-04-17 |
| 60687-0149-94 | 20 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-149-94) / 1 TABL... | Capecitabine | American Health Packaging | 2016-03-07 |
| 61269-0475-12 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61269-475-12) | XELODA | H2-Pharma, LLC | 1998-04-30 |
| 62756-0238-18 | 1000 TABLET, FILM COATED in 1 BOTTLE (62756-238-18) | Capecitabine | Sun Pharmaceutical Industries, Inc. | 2019-09-01 |
| 62756-0238-86 | 60 TABLET, FILM COATED in 1 BOTTLE (62756-238-86) | Capecitabine | Sun Pharmaceutical Industries, Inc. | 2019-09-01 |
| 62756-0238-88 | 100 TABLET, FILM COATED in 1 BOTTLE (62756-238-88) | Capecitabine | Sun Pharmaceutical Industries, Inc. | 2019-09-01 |
| 62756-0239-18 | 1000 TABLET, FILM COATED in 1 BOTTLE (62756-239-18) | Capecitabine | Sun Pharmaceutical Industries, Inc. | 2019-09-01 |
| 62756-0239-20 | 120 TABLET, FILM COATED in 1 BOTTLE (62756-239-20) | Capecitabine | Sun Pharmaceutical Industries, Inc. | 2019-09-01 |
| 62756-0239-83 | 30 TABLET, FILM COATED in 1 BOTTLE (62756-239-83) | Capecitabine | Sun Pharmaceutical Industries, Inc. | 2019-09-01 |
| 67877-0458-12 | 120 TABLET, FILM COATED in 1 BOTTLE (67877-458-12) | Capecitabine | Ascend Laboratories, LLC | 2017-11-25 |
| 67877-0458-30 | 30 TABLET, FILM COATED in 1 BOTTLE (67877-458-30) | Capecitabine | Ascend Laboratories, LLC | 2017-11-25 |
| 67877-0458-60 | 60 TABLET, FILM COATED in 1 BOTTLE (67877-458-60) | Capecitabine | Ascend Laboratories, LLC | 2019-05-01 |
| 67877-0459-12 | 120 TABLET, FILM COATED in 1 BOTTLE (67877-459-12) | Capecitabine | Ascend Laboratories, LLC | 2019-05-01 |
| 67877-0459-30 | 30 TABLET, FILM COATED in 1 BOTTLE (67877-459-30) | Capecitabine | Ascend Laboratories, LLC | 2017-11-25 |
| 67877-0459-60 | 60 TABLET, FILM COATED in 1 BOTTLE (67877-459-60) | Capecitabine | Ascend Laboratories, LLC | 2017-11-25 |
| 68001-0487-06 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68001-487-06) | CAPECITABINE | BluePoint Laboratories | 2021-02-22 |
| 68001-0488-07 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68001-488-07) | CAPECITABINE | BluePoint Laboratories | 2021-02-22 |
| 68001-0643-06 | 60 TABLET, FILM COATED in 1 BOTTLE (68001-643-06) | Capecitabine | BluePoint Laboratories | 2025-04-18 |
| 68001-0644-07 | 120 TABLET, FILM COATED in 1 BOTTLE (68001-644-07) | Capecitabine | BluePoint Laboratories | 2025-04-22 |
| 69097-0948-08 | 120 TABLET, FILM COATED in 1 BOTTLE (69097-948-08) | Capecitabine | Cipla USA Inc. | 2023-07-01 |
| 69097-0949-03 | 60 TABLET, FILM COATED in 1 BOTTLE (69097-949-03) | Capecitabine | Cipla USA Inc. | 2023-07-01 |
| 70756-0815-60 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (70756-815-60) | Capecitabine | Lifestar Pharma LLC | 2020-09-01 |
| 70756-0816-22 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (70756-816-22) | Capecitabine | Lifestar Pharma LLC | 2020-09-01 |
| 72205-0006-60 | 60 TABLET, FILM COATED in 1 BOTTLE (72205-006-60) | Capecitabine | Novadoz Pharmaceuticals LLC | 2018-07-21 |
| 72205-0007-92 | 120 TABLET, FILM COATED in 1 BOTTLE (72205-007-92) | Capecitabine | Novadoz Pharmaceuticals LLC | 2018-07-21 |
| 72485-0205-12 | 1 BOTTLE in 1 CARTON (72485-205-12) / 120 TABLET, FILM COAT... | Capecitabine 500mg | Armas Pharmaceuticals Inc. | 2019-03-01 |
| 72603-0303-01 | 120 TABLET, FILM COATED in 1 BOTTLE (72603-303-01) | capecitabine | NorthStar RxLLC | 2024-12-01 |
| 82009-0112-12 | 120 TABLET in 1 BOTTLE (82009-112-12) | Capecitabine | Quallent Pharmaceuticals Health LLC | 2023-07-21 |
| 82249-0207-60 | 60 TABLET, FILM COATED in 1 BOTTLE (82249-207-60) | Capecitabine | CivicaScript LLC | 2025-06-26 |
| 82249-0210-12 | 120 TABLET, FILM COATED in 1 BOTTLE (82249-210-12) | Capecitabine | CivicaScript LLC | 2025-06-26 |
| 82511-0001-15 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (82511-001-15) | Capecitabine | Teyro Labs Private Limited | 2022-09-01 |
| 82511-0002-50 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (82511-002-50) | Capecitabine | Teyro Labs Private Limited | 2022-02-16 |
Observed labelers:
Ascend Laboratories, LLC (6) ·
Sun Pharmaceutical Industries, Inc. (6) ·
Aurobindo Pharma Limited (4) ·
BluePoint Laboratories (4) ·
Dr. Reddy's Laboratories Limited (4) ·
Camber Pharmaceuticals, Inc. (3)
· +13 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J8522 | Capecitabine, oral, 50 mg | 22 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.